1）津谷喜一郎（編）. くすりギャップ：世界の医薬品問題の解決を目指して. ライフサイエンス出版; 2006.
2）Wardell WM. Introduction of new therapeutic drugs in the United States and Great Britain: an international comparison. Clin Pharmacol Ther 1973; 14: 773−90.
3）Wardell WM. The drug lag revisited: comparison by therapeutic area of patterns of drugs marketed in the United States and Great Britain from 1972 through 1976. Clin Pharmacol Ther 1978; 24: 499−524.
4）Andersson F. The drug lag issue: the debate seen from an international perspective. Int J Health Ser 1992; 22(1): 53−72.
5）Parker J. Who has a drug lag?. J Soc Admin Pharm 1989; 6: 138−52.
6）Parker J. Who has a drug lag?. Managerial and Decision Economics. 1989; 10: 299−309.
7）Keitin K, Mattison N, Northington N, Lasagna L. The drug lag: an update of new drug introductions in the United States and in the United Kingdom, 1977 through 1987. Clin Pharmacol Ther 1989; 46: 121−38.
8）Danzon PM, Wang YR, Wang L. The impact of price regulation on the launch delay of new drugs-evidence from twenty-five major markets in the 1990s. Health Econo 2005; 14: 269−92.
9）島谷克義, 須藤隆夫. 開発戦略における日本の課題. 医療と社会 2005; 15(1):43−50.
Available from URL:http://www.iken.org/activity/paper/past/h17/pdf/15-1-6.pdf[Accessed
April 10, 2008]
10）福原浩行. 医薬品の世界初上市から各国における上市までの期間：日本の医薬品へのアクセス改善に向けて. 医薬産業政策研究所リサーチペーパー・シリーズNo.31.
2006.
Available from URL:http://www.jpma.or.jp/opir/research/article31.html[Accessed
May 30, 2006]
11）安田邦章, 小野俊介. 日本における新医薬品の承認審査期間：2007年度調査. 医薬産業政策研究所リサーチペーパー・シリーズNo.37. 2007.
Available from URL: http://www.jpma.or.jp/opir/research/
article37.html [Accessed Jan. 27, 2008]
12）厚生労働省. 第１回「有効で安全な医薬品を迅速に提供するための検討会」資料3.
Available from URL:http://www.mhlw.go.jp/shingi/2006/10/s1030-8.html [Accessed Otc.10, 2006]
13）Tsuji K, Tsutani K. Personal imports of drugs to Japan in 2005: an analysis
of import certificates. J Clin Pharm Ther 2008; 33(5): 545−52.
14）厚生労働省. 未承認薬使用問題検討会議．
Available from URL:http://www.mhlw.go.jp/shingi/other.html#iyaku [Accessed Oct.10, 2006]
15）文部科学省・厚生労働省. 全国治験活性化3ヵ年計画. 文部科学省・厚生労働省; 2003.
Available from URL:http://www.mhlw.go.jp/shingi/2005/06/dl/s0630-7n.pdf [Accessed Oct.10, 2006]
16）厚生労働省. 治験のあり方に関する検討会.
Available from URL: http://www.mhlw.go.jp/shingi/other.html#iyaku[Accessed Jan.20, 2007]
17）文部科学省・厚生労働省. 新たな治験活性化5ヵ年計画. 文部科学省・厚生労働省; 2007.
Available from URL:http://www.mhlw.go.jp/shingi/2007/03/s0330-5.html [Accessed Jan.20, 2007]
18）厚生労働省. 有効で安全な医薬品を迅速に提供するための検討会.
Available from URL:http://www.mhlw.go.jp/shingi/other.html#iyaku [Accessed Jan. 20, 2007]
19）文部科学省・厚生労働省・経済産業省. 革新的医薬品・医療機器創出のための5ヵ年戦略. 文部科学省・厚生労働省・経済産業省; 2007.
Available from URL:http://www.mhlw.go.jp/houdou/2007/04/h0427-3.html [Accessed May 10, 2007]
20）Anderson TM. Introduction to multiple statistical analysis. John Wiley & Sons; 1958.
21）厚生労働省審査管理課長. HIV感染症治療薬の製造又は輸入承認申請について（医薬審1015号）. 平成10年11月12日.
22）安田邦章, 小野俊介. 日本における新医薬品の開発期間：臨床開発期間と承認審査期間. 医薬産業政策研究所リサーチペーパー・シリーズNo.42. 2008.
Available from URL:http://www.jpma.or.jp/opir/research/article42.html[Accessed Jan. 27, 2009]
23）Tsuji K, Tsutani K. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations. Eur J Pharm Biopharm 2008; 68(3): 496−502.
24）Tsuji K, Tsutani K. Follow the leader. Nature 2008; 453(7197): 851−2.
25）Oxfam International. Ending the R&D Crisis in Public Health: promoting
pro-poor medical innovation. Oxfam Briefing Paper 122. 2008.
Available from URL:http://www.oxfam.org/files/bp122-randd-crisis-public-health.pdf [Accessed Feb. 23, 2009]
26）Drugs for Neglected Diseases.
Available from URL:http://www.dndi.org/[Accessed Feb.23,
2009]
27）Global Forum for Health Research.
Available from URL:http://www.globalforumhealth.org/Site/000__Home.php [Accessed Feb.27, 2009]
28）FDA. Amendment to the Food and Drug Administration Revitalization Act. 2007.
Available from URL:http://www.fda.gov/oc/initiatives/HR3580.pdf [Accessed Feb. 23, 2009]
29）FDA. New drug, antibiotic, and biological drug product regulations; accelerated approval. Federal Register 1992; 57(239): 58942−60. Available from URL:http://www.fda.gov/cder/guidance/append4.pdf [Accessed May 10, 2007]
30）EMEA. Guideline of procedures for the granting of a marketing authorization under exceptional circumstances, pursuant to Article 14(8) of regulation (EC) No 726/2004. London: 2005. Available from URL: http://www.emea.europa.eu/pdfs/human/euleg/35798105en.pdf[Accessed May 10, 2007]
31）EMEA. Guideline of the scientific application and the practical arrangements
necessary to implement commission regulation (EU) No 507/2006 on the conditional
marketing authorization for medicinal products for human use falling within the
scope of Regulation (EC) no 726/2004. London; 2006.
Available from URL:http://www.emea.europa.eu/pdfs/human/regaffair/50995106en.pdf [Accessed May 10, 2007]
32）FDA. Orphan Drug Act (as amended) Available fromURL:http://www.fda.gov/orphan/oda.htm[Accessed Dec. 1, 2006]
33）EMEA. Orphan drugs and rare diseases at a glance. London; 2007.
Available from URL:http://www.emea.europa.eu/pdfs/human/comp/29007207en.pdf [Accessed Dec. 1, 2006]
34）EMEA. Committee for orphan medicinal products Rules of procedure. London; 2007.
Available from URL:http://www.emea.europa.eu/pdfs/human/comp/821200en.pdf [Accessed Dec. 1, 2006]
35）European Commission. Guideline on the format and content of applications for designation as orphan medicinal products and the transfer of designations from one sponsor to another, 9 July 2007. Brussels; 2007.
Available from URL:http://www.emea.europa.eu/pdfs/human/comp/628300en.pdf [Accessed Dec.1, 2006]
36）医薬基盤研究所. 稀少疾病用医薬品開発振興業務．
Available from URL:http://www.nibio.go.jp/shinko/orphan.
html[Accessed Dec.10, 2006]
37）白神誠, 中井清人. オーファンドラッグ開発の現状の分析. 臨床薬理 1999; 30(4): 681−701.
38）辻香織. 未承認薬使用に関するヨーロッパ各国の制度. 医療と社会 2008; 18(2): 243−56.